Sean Doherty

IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.